BD Medical's fiscal year 2025 performance exceeds expectations, with significant stock price fluctuations

2026-03-03 06:12:33

Medtronic’s Q4 FY2025 revenue reached $5.89 billion, up 8% year-over-year, with adjusted EPS of $3.96, exceeding expectations; full-year revenue was $21.84 billion, up 8.2%. The life sciences business recovered, and the diagnostics segment returned to growth.

Institutional Views

Citigroup maintains a “Buy” rating with a target price of $232; TD Cowen raises its target price to $189 and maintains a “Hold” rating; Barclays and other institutions also adjusted their target prices. The market is focused on its strategic focus after divestitures.

Recent Stock Performance

The stock price has fluctuated significantly over the past 7 days, with a total increase of 9.87% and a volatility of 15.58%. On February 11, the closing price was $180.62, up 5.21% for the day; on February 12, it closed at $178.32, down 1.27%. Trading volume was active, with a turnover of $1.065 billion on February 11.

Recent Events

At the industry level, the China International Medical Equipment and Devices Trading Platform launched, promoting globalization expectations for the sector. At the company level, Becton Dickinson completed the merger related to Medtronic’s business, establishing four new divisions focused on life sciences and diagnostics.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.